Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario Related: Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence. RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19. [Preprint] RCT: Fluvoxamine reduced the risk for ER visits and […]
The post Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know. appeared first on Links Medicus.
Self-isolation for those with COVID-19 can end after 5 full days following 2 negative LFD tests – Department of Health and Social Care Commentary on Twitter (thread – click for more) Self-isolation period for people infected with COVID in England will be reduced to 5 days from Monday 17 Jan. But it's conditional: 2 […]
The post New UK Guidance: Self-isolation for those with COVID-19 can end after 5 full days following 2 negative rapid lateral flow tests – “The default self-isolation period continues to be 10 days, and you may only leave self-isolation early if you have taken 2 rapid lateral flow tests and do not have a temperature in line with guidance”. appeared first on Links Medicus.
Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection – JAMA Surgery Commentaries: Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery Can weight loss help protect against Covid-19? – CNN
The post Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity. appeared first on Links Medicus.
Omicron Is Forcing Us to Rethink Mild COVID – The Atlantic
The post Perspective: Omicron is forcing us to rethink mild COVID. appeared first on Links Medicus.
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial – JAMA Network Open Related: M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death. RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of […]
The post RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19. appeared first on Links Medicus.
‘Killer’ immune cells still recognize Omicron variant – Nature See also: T-cells: the superheroes in the battle against omicron – The Conversation
The post ‘Killer’ immune cells still recognize Omicron variant. appeared first on Links Medicus.
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
The post Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized. appeared first on Links Medicus.
A clinical case definition of post-COVID-19 condition by a Delphi consensus – The Lancet Infectious Diseases Commentary on Twitter New Review: A clinical case definition of post-#COVID19 condition by a Delphi consensus https://t.co/AoWBgCeMq5 pic.twitter.com/kAW1YY6kgr — The Lancet Infectious Diseases (@TheLancetInfDis) December 22, 2021
The post A clinical case definition of post-COVID-19 condition by a Delphi consensus. appeared first on Links Medicus.
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa – New England Journal of Medicine Commentary: BNT162b2 still effective, but less so, against Omicron – HealthDay
The post An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant. appeared first on Links Medicus.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right? Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress Commentary on Twitter Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course […]
The post RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19. appeared first on Links Medicus.